Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million

Xlife Sciences AG / Key word(s): Disposal/Investment Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million 18-Oct-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Zurich, 18th of October 2023: Xlife Sciences AG (SIX: XLS) has secured a strategic collaboration with 4D Lifetec AG that marks a transformative phase in the healthcare sector, fusing financial capabilities with avant-garde technology, aimed at revolutionizing early cancer detection.

The agreement involves a two-pronged approach: Firstly, 4D Lifetec is enhancing the capabilities of its 4D Lifetest in the realm of digital health with the acquisition of Xlife Sciences portfolio company x-diagnostics GmbH in a share deal and secondly Xlife Sciences makes a direct cash investment in 4D Lifetec. The total transaction value is CHF 23.3 million.  Xlife Sciences is therefore establishing its position as 20% shareholder in 4D Lifetec. The portfolio company x-diagnostics GmbH was founded 2021 in Zurich (Xlife Sciences has 100% ownership) and develops products which use artificial intelligence in the field of oncology, especially in the early detection of cancer cells.

This partnership accentuates Xlife Sciences' and 4D Lifetec dedication to champion innovation and deliver optimal patient care. In particular, one of the major goals to establish this position is laying the groundwork for stock market readiness in the US, which is facilitated by 4D Lifetec already running an entity in the US.

The core mission of 4D Lifetec, empowering patients via early-stage cancer detection, is bolstered by their pioneering immuno-oncology biomarker, the 4D Lifetest. These tests, targeting early-stage cancer (I and II), promise proactive health safeguards and effective screening of patients. The easy-to-use IVD certified blood test enables a unique high-throughput analysis of patient samples, providing a powerful data set that now becomes accessible to train AI through the transaction. Backed up with a substantial investment, 4D Lifetec gains a doorway to innovative AI that will redefine the landscape of cancer diagnosis and access to the digital health network of Xlife Sciences.